Effect of a platelet activating factor antagonist (CV6209) on shock caused by temporary hepatic inflow occlusion
- 1 January 1990
- journal article
- research article
- Published by Elsevier in Life Sciences
- Vol. 47 (6) , 565-570
- https://doi.org/10.1016/0024-3205(90)90617-z
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats.Journal of Clinical Investigation, 1987
- Possible role of platelet activating factor (PAF) in disseminated intravascular coagulation (DIC), evidenced by use of a PAF antagonist, CV-3988Life Sciences, 1986
- PLATELET ACTIVATING FACTOR: A BIOLOGICALLY ACTIVE PHOSPHOGLYCERIDEAnnual Review of Biochemistry, 1986
- For How Long Can the Liver Tolerate Ischaemia?European Surgical Research, 1986
- Platelet activating factor (PAF) involvement in endotoxin-induced hypotension in rats. studies with paf-receptor antagonist kadsurenoneBiochemical and Biophysical Research Communications, 1985
- Is platelet activating factor (PAF) a mediator of endotoxin shock?European Journal of Pharmacology, 1985
- Tolerance of the cirrhotic liver to normothermic ischemia: A clinical study of 15 patientsThe American Journal of Surgery, 1984
- BACKGROUND AND PRESENT STATUS OF RESEARCH ON PLATELET‐ACTIVATING FACTOR (PAF‐ACETHER)Annals of the New York Academy of Sciences, 1981
- NORMOTHERMIC HEPATIC VASCULAR EXCLUSION FOR EXTENSIVE HEPATECTOMY1978
- Regional PancreatectomyAnnals of Surgery, 1977